1 active not recruiting, 1 completed, 1 suspended, 1 withdrawn. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Suspended 1 |
| Phase 1 | 2 | Active not recruiting 1, Suspended 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow E7777 fusion protein: new trials by email Literature Review of E7777 fusion protein trials Research Report on E7777 fusion protein
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Pembrolizumab, E7777 - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Alexander B Olawaiye, MD | 25 | 2022-09-30 | 2026-05-29 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-01-15 |
| Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma E7777 - Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | Phase 2 | Completed | Eisai Co., Ltd. | 45 | 2016-03-28 | 2021-07-15 |
| A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma E7777 - Peripheral T-Cell Lymphoma | Phase 3 | Withdrawn | Eisai Inc. | 2011-03-01 | 2013-11-18 |
Lymphoma, T-Cell, Peripheral (2) · Carcinoma, Ovarian Epithelial (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Cutaneous (1) · Turcot syndrome (1)
Alexander B Olawaiye, MD (1) · Eisai Co., Ltd. (1) · Eisai Inc. (1) · Masonic Cancer Center, University of Minnesota (1)
United States (3) · Japan (1)
Alexander Olawaiye, MD (1) · Chean Eng Ooi (1) · Veronika Bachanova, MD (1)